AMERICAN ACADEMY OF ALLERGY ASTHMA AND IMMUNOLOGY

Lobbying Spend

—

Filings

Firms Hired

Active Period

2000–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	4	1
2024	—	4	1
2023	—	4	1
2022	—	4	1
2021	—	4	1
2020	—	4	1
2019	—	5	1
2018	—	4	1
2017	—	5	1
2013	—	2	1
2012	—	4	1
2011	—	4	1
2010	—	5	1
2009	—	4	1
2008	—	5	1
2007	—	2	1
2006	—	2	1
2005	—	2	1
2004	—	1	1
2003	—	1	1
2002	—	1	1
2001	—	2	1
2000	—	2	1

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
HART HEALTH STRATEGIES	—	41
WASHINGTON HEALTH ADVOCATES	—	37

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	72
SENATE	72
Natl Institutes of Health (NIH)	32
Food & Drug Administration (FDA)	21
Health & Human Services, Dept of (HHS)	11
Centers For Medicare and Medicaid Services (CMS)	2

Most frequently reported lobbying issues

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 3627112th Congress

School Access to Emergency Epinephrine Act

2012 · fourth_quarter · Firm: WASHINGTON HEALTH ADVOCATES

Cited source text and reported amounts

funding for medical research on asthma/allergic diseases; S 1884/HR 3627, School Access to Emergency Epinephrine Act

Client expense: — · Firm income: $31,000

Matched citations: HR 3627

AMERICAN ACADEMY OF ALLERGY ASTHMA AND IMMUNOLOGY — Lobbying Disclosure | Poliscope